EFFECTS OF ORAL ALFACALCIDOL ON MATURATION OF DENDRITIC CELLS IN GRAVES’ DISEASE PATIENTS: A DOUBLE-BLINDED RANDOMIZED CLINICAL TRIAL

DYAH PURNAMASARI1,5*, SAMSURIDJAL DJAUIZI2, SITI SETIATI1, ALIDA HARAHAP1, TJOKORDA G PEMAYUN2, JOEDO PRIHARTONO6, PRADANA SOEWONDO1

1Department of Medicine, Division of Endocrinology, Faculty of Medicine Universitas Indonesia, Indonesia. 2Department of Medicine, Division of Allergy Immunology, Faculty of Medicine Universitas Indonesia, Indonesia. 3Department of Medicine, Division of Geriatrics, Faculty of Medicine Universitas Indonesia, Indonesia. 4Department of Clinical Pathology, Division of Immunology, Faculty of Medicine Universitas Indonesia, Indonesia. 5Department of Medicine, Division of Endocrinology, Faculty of Medicine Universitas Diponegoro, Indonesia. 6Departement of Community Medicine, Faculty of Medicine Universitas Indonesia, Indonesia. Email: dyah_p_irawan@yahoo.com

INTRODUCTION

Previously, Graves’ disease (GD) had been considered as organ-specific autoimmune disease until an animal study showed that mice with total thyroidectomy still had a high level of cytokine interleukin-12 (IL-12) from its spleen [1]. IL-12, inflammatory cytokine, primarily comes from dendritic cells (DC). In autoimmune disease, maturation of DC gives a potential contribution to the development and maintenance of immune response [2].

Mature DCs have a strong positive expression on major histocompatibility complex (MHC), costimulatory, and DC maturation molecules (HLA-DR, CD80, CD83, and CD14), and mannose receptor (MR/CD206). In contrast, immature DCs have a weak positive expression on MHC, costimulatory, and DC maturation molecules, but they have strong markers for monocytoid monocytes and MR. Beside IL-12, DC also produce low level of IL-10 which has anti-inflammatory properties. The balance of IL-12 and IL-10 contributes to the activation of naïve T lymphocyte cells [2].

DC maturation is influenced by genetic and environmental factors. The genetic factors affecting DC maturation are HLA gene [3] and inflammatory cytokines genes [4,5], while the environmental factors affecting DC maturation are infection [6], thyroid hormone [7], hormonal changes in women related to menstruation approaches, the use of sex-steroid hormone drug [8], immunosuppressants [9], and vitamin D [10]. The previous studies among systemic lupus erythematosus (SLE), multiple sclerosis (MS), and Crohn’s disease showed that in vitro 1,25 dihydroxy vitamin D (1,25-D3) impaired the maturation of DC in monocyte-derived DC (MDDC) cultures [10-12].

Although the effect of 1,25-D3 on immunology process was clearly proved in in vitro study, the advantage of vitamin D supplementation among SLE, MS, and Crohn’s disease is still on debate [13-16].

In GD, previous studies have showed a relationship between vitamin D deficiency, the polymorphisms of the vitamin D receptor, and vitamin D binding protein with the occurrence of GD [17,18]. Vitamin D levels have association with remission status [19]. A study by Kawakami-Tani et al. [20] in Japan among new onst GD patients showed that alfacalcidol (1α-D3) supplementation along with antithyroid drug (ATD) can reduce the level of thyroid hormone which was faster in the treatment group compared to placebo group. Those effects are likely due to direct antithyroid actions of 1α-D3 on the thyroid gland. However, the immunological process behind the 1α-D3 induced-thyroid hormone reduction is not well defined yet.

In the previous study we already showed that in vitro 1,25-D3 supplementation in MDDC cultures of GD patients will interfere the maturation of DC by decreasing the expression of HLA class II molecule (HLA-DR), costimulatory molecules (CD80 and CD40), and DC marker (CD83) as well as increasing the expression of monocyte (CD14) [21]. The result showed that in vitro 1,25-D3 intervention has a positive effect in the immunology process among GD patients. In this study, we aim to evaluate the effect of in vivo 1α-D3 supplementation to DC maturation in GD patients.

METHODS

Design
Between May 2014 and March 2015, we found 29 GD patients who were still in hyperthyroid condition at the outpatient clinic of...
Endocrinology Department of Dr. Cipto Mangunkusumo Hospital in Jakarta, Indonesia. The diagnosis of GD was made based on clinical manifestation (tachycardia, fine tremor, excessive sweat, diffuse struma, and ophthalmopathy) and laboratory data (low thyroid stimulating hormone [TSH] level, increased fT4 level, and positive thyroid receptor antibody [TRAb]). Patients who took vitamin D supplementation were pregnant or had comorbidities, i.e., diabetes mellitus (DM), chronic kidney disease, and other autoimmune diseases were excluded from the study. Out of 29 patients, 25 patients completed the study, while 4 patients were unable to complete the study due to laboratory technical problems.

This is a double-blinded, randomized clinical trial (RCT) study. A 4-block randomization was performed in 25 GD patients to categorize them into two groups, i.e., the treatment and placebo group. There were 12 GD patients in the treatment group who received propylthiouracil (PTU) 300 mg daily with supplementation of 1α-D3 at dose of 1.5 mcg once daily for 8 weeks; while 13 GD patients in the placebo groups received PTU 300 mg daily and placebo tablets for 8 weeks (Fig. 1).

The patients were scheduled to have hospital visits every two weeks, and the responsible physician evaluated the clinical and laboratory data. All patients gave their informed consent. The study received approval from the Ethics Committee of Faculty of Medicine, Universitas Indonesia no. 489/Hz.F1/ETIK/2014.

Biological materials and measurements
After randomization, blood specimens were collected from venous blood at certain times; then underwent centrifugation. The serum was stored at −80°C for laboratory evaluation, and the rests were processed for MDDC cultures. Laboratory evaluation consists of vitamin 25-D3 (Euroimmun) and TRAb (DRG) level before supplementation as well as TSH and fT4 (ROCHE) level before supplementation, at week 4 and week 8 (after supplementation).

MDDC culture: Mo-DC differentiation
MDDC cultures were performed before and after supplementation. The isolation of PBMC and monocytes followed by lipopolysaccharide (LPS) stimulation was done based on the method that has been performed by Budiyati et al. [22]. The isolation of PBMC was conducted through density differences using Ficoll-Paque premium (GE Healthcare). The specimens were dissolved in the Roswell Park Memorial Institute (RPMI) medium at cell density of 1 × 10⁶/ml. Isolation of monocytes was performed using the adherence method. One ml of DC culture media (DCCM) was added after the monocytes adhered to the base of the plate. DCCM consists of RPMI 1640 medium, 10% fetal bovine serum (Gibco), 800 U/ml of Granulocyte-macrophage colony-stimulating factor (BD Bioscience Pharmingen), and 1000 U/ml of IL-4 (BD Bioscience Pharmingen). At the end of those procedures, the cells then were incubated at 37°C with CO₂ 5% for the next 5 days.

MDDC culture: DC maturation and harvesting
Additional 500 ng LPS was added (Sigma-Aldrich) to cultures on the fifth day (D5), and the incubation was then continued for further 2 days. After cell harvesting and separation procedures from the supernatant, the cells can be processed for monoclonal antibody staining, while the supernatant was stored at −20°C for evaluating IL-12 and IL-10 cytokines.

Flow cytometry analysis
The flow cytometry analysis was operated using fluorescence-activated cell sorting (FACS) Calibur (BD Biosciences). The fluorochrome-conjugated antibodies (BD Biosciences Pharmingen) used in flow cytometry technique are HLA-DR fluorescein isothiocyanate (FITC) (G46-6, mouse IgG2aκ), CD40 phycoerythrin (PE) (5C3, mouse IgG1κ), CD80 PE-Cyanine5 (PECy5) (L307,4, mouse IgG1κ), CD83 PECy5 (HB15e, mouse IgG1κ), CD206 PE (19,2, mouse IgG1κ), and CD14 FITC (M5E2, mouse IgG2aκ).

The expression of HLA-DR, CD80, CD40, and CD206 were presented in the form of mean fluorescence intensities, while the expression of CD14

---

**Fig. 1: Flow diagram of the randomization**
and CD83 were presented in numbers of positive cells. Measurement of cytokine levels (IL-12 and IL-10) was done using Human IL-12 p70 (Quantikine HS ELISA Kit - R&D Systems kit) and Human IL-10 (Quantikine ELISA Kit - R&D Systems).

Statistical analysis
Data were analyzed following per-protocol analysis and presented in mean value ± standard deviation when they have normal distribution and in median value (minimum and maximum value) when they did not have normal distribution. The evaluation of mean or median value for DC marker expression and ratio of IL-12/IL-10 cytokines between before and after supplementation in the treatment and placebo group were carried out using paired t-test when the data had normal distribution and using Wilcoxon test when the data were not normally distributed.

RESULTS
Subject characteristics can be seen in Table 1. Data are presented in mean value ± SD when they were normally distributed and in median value (minimum and maximum value) when they did not have normal distribution.

Following the randomization, there were two study groups (the treatment and placebo group), which had similar baseline characteristics (p>0.05).

Effects of in vivo 1α-D3 on the expression of DC markers and the ratio of cytokines IL-12/IL-10 in MDDC cultures of GD patients
The effects of in vivo 1α-D3 supplementation on DC maturation were evaluated by comparing each expression of DC marker in the MDDC culture before and after 8-week supplementation. The expression of CD80 on the 7th day of MDDC culture was lower in the treatment group (p=0.48) after supplementation; while in the placebo group, there was an increase (p=0.22). The expression of CD206 on the 7th day of MDDC culture increased in the treatment group (p=0.47); while in the placebo group, it decreased (p=0.18) (Fig. 2). Both CD40 and CD83 expression in both groups increased insignificantly, while the expression of CD14 decreased insignificantly in both groups (p=0.53 and p=0.08).

Effects of oral 1α-D3 on fT4 level in GD patients
As many 8 out of 12 GD patients in treatment group and 6 out of 13 GD patients in placebo group still had high fT4 level. Both groups had lower thyroid level (fT4) after 8-week supplementation (3.29±2.05 vs. 2.88±3.01; p=0.34). The percentage of lower fT4 level in both groups were not different (58.49 (0.00-89.33 vs. 76.05-88.16); p=0.77) (Fig. 3).

DISCUSSION
DC has a significant role in initiating and maintaining the autoimmune response [2]. DC maturation process is influenced by genetic and environmental factors. One of the environmental factors contributing to DC maturation is vitamin D. As an immunomodulator; vitamin D regulates several innate and adaptive immune responses found in autoimmune diseases, including inhibition of DC maturation [23]. This study reveals further knowledge regarding the immunoregulatory effect of vitamin D, mainly on inhibition of DC maturation in GD patients. This is the first study reporting the effect of oral vitamin D on inhibition of DC maturation in GD patients.

The mean value of vitamin in 25-D3 level in GD patients of our study was 25±6.62 ng/ml. This value is higher than a value reported in Japan. Yasuda et al. [19] reported the mean value of vitamin 25-D3 level in GD patients was 14.5±2.9 ng/ml in non-remission versus 18.2±5.1 ng/ml in remission group. About 76% patients in our study still had vitamin D insufficiency (<30 ng/ml). This finding is similar to studies on other autoimmune diseases [24].

Effects of in vivo 1α-D3 on the expression of DC markers in MDDC cultures of GD patients
This study design refers to a study conducted by Kawakami-Tani et al. which reported that there is a greater reduction of fT4 level in GD patients receiving methimazole (MMI) and 1α-D3 supplementation than those who only receive MMI alone [20]. The present study wants to identify whether the greater reduction of the fT4 level is also accompanied by immunological process, particularly inhibition of DC maturation on molecular aspects.

The results of our study demonstrate that oral supplementation of 1α-D3 for 8 weeks has not yet inhibited DC maturation, which is not significant compared to the placebo group.

Table 1: Subject characteristics (n=25)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean value±SD</th>
<th>Median (minimum-maximum)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>36±8.81</td>
<td>24 (2-26.6)</td>
</tr>
<tr>
<td>Duration of illness (months)</td>
<td>0.01</td>
<td>5.04 (2.51-7.77)</td>
</tr>
<tr>
<td>TSH (µIU/l)</td>
<td></td>
<td>14.174 (3.304-87.738)</td>
</tr>
<tr>
<td>fT4 (ng/dl)</td>
<td></td>
<td>25±6.62</td>
</tr>
<tr>
<td>TRAb (U/l)</td>
<td></td>
<td>11.3±0.05</td>
</tr>
<tr>
<td>Ca ion (mmol/l)</td>
<td></td>
<td>1.13±0.05</td>
</tr>
</tbody>
</table>

Data are presented in mean value±SD when they were normally distributed and in median value (minimum and maximum value) when they did not have normal distribution.

Fig. 2: The expression of CD206 and CD80 in cultures before and after the supplementation of 1α-D3
characterized by insignificant lower expression of CD80 costimulatory molecule and persistent expression of MR (CD206). Although the results have not been significant yet, oral supplementation of 1α-D3 tends to demonstrate inhibition of DC maturation, which is characterized by lower expression of costimulatory molecule and the persistence of MR expression, while placebo supplementation tends to have higher expression of costimulatory molecule and lower MR expression. Lower costimulatory molecule expression and the persistence of MR molecules suggest that there is inhibition of DC maturation. There were no significant differences between oral 1α-D3 supplementation and placebo treatment on other DC markers, i.e., CD83, CD40, and CD14.

Our study is the first RCT evaluating the effect of oral vitamin D on immune cells profile (DC maturation) in GD. It is also the first study observing the effect of oral vitamin D supplementation on MR expression in autoimmune disease. A systematic review in 2012 about vitamin D supplementation in autoimmune diseases shows that out of 270 analyzed studies, there are only two RCTs; while others are observational study. Both RCTs reported the effect of 0.5 mg/c oral 1α-D3 supplementation on lower needs of insulin and improved function of beta cells in patients with DM1 [25]. There is one RCT in 2013, which has not been incorporated into the systematic review. It discussed the effect of oral vitamin D on improved disease activity, inflammatory cytokines, and hemostatic profile of patients with SLE [15]. The previous three RCTs involving a greater number of autoimmune patients did not evaluate the profile of immune cells.

Our study is the second study which evaluates the effect of oral vitamin D on DC maturation in autoimmune disease. The first study is a study of drug-placebo without randomization conducted by Bartels et al. in 19 patients with Crohn’s disease. The results of that study showed that there was significant lower expression of costimulatory molecule (CD80) (p=0.04) in the 25-D3 group than those in placebo group, but the expressions of HLA and other costimulatory molecule were not different (p>0.05) [26].

In Bartels et al. study, in vivo supplementation only demonstrated partial changes on DC maturation markers [26]. In our study, in vivo vitamin D supplementation reduced the expression of costimulatory molecule (CD80) and maintained the expression of MR (CD206) insignificantly in treatment group. Although the results were not significant, they showed the trend of vitamin D’s positive effect since reverse changes occurred in placebo group, i.e., increased expression of costimulatory molecule and reduced MR expression.

Effects of in vivo 1α-D3 on ratio of cytokines IL-12/IL-10 level in MDDC cultures of GD patients

Our study is the first study that evaluates the effect of oral vitamin D supplementation on the ratio of inflammatory (IL-12) and anti-inflammatory (IL-10) cytokine level in supernatant of MDDC culture of patients with autoimmune disease. Changes in IL-12/IL-10 ratio are strongly affected by IL-12 cytokine. Our study has not been able to show the effect of oral vitamin D supplementation on the ratio of IL-12/IL-10 levels in patients with GD since the ratio of IL-12/IL-10 levels among two groups was not significant.

Thyroid hormone (fT4) affects DC maturation; therefore, it correlates with IL-12 cytokines produced by DC [7]. The IL-12 cytokine level is high in GD patients who are still hyperthyroid and decreases with ATD treatment. This IL-12 decrement is correlated with decreased fT4 level (r=0.5) [27]. In our study, we did not find any correlation between fT4 and IL-12 cytokine level (r=−0.06). The absence of correlation between fT4 and IL-12 cytokine level in our study might be due to the relatively short monitoring period (8 weeks) compared to other studies. A short monitoring period caused IL-12 level was not optimally reduced; therefore, our study did not find any significant correlation between fT4 and IL-12 levels. A study that shows correlation between fT4 and IL-12 cytokine levels had 12 months of monitoring period, and it demonstrates continuous reduction of IL-12 level until the 5th month of treatment although the fT4 level has reached the normal limit on the 2nd month of treatment [27].

Another clinical study associated with the role of vitamin D from sun exposure on changes of cytokines of GD patients was conducted in Jakarta with 32 GD patients, who were categorized into 2 groups, i.e., the exposure and non-exposure groups [28]. Results of the study showed that sun exposure three times a week for 20-30 minutes of each exposure for four weeks increased vitamin D level as much as 20% and inhibited the increment of IL-4 cytokine levels. IL-4 cytokine is a major stimulant for DC for IL-12 secretion; therefore, it is assumed that lower IL-4 cytokine will reduce IL-12 cytokine and it may lead to reducing activation of T cells. The study of sun exposure describes the important role of cytokines in GD [29].

Effects of oral 1α-D3 on fT4 level in GD patients

A study by Kawakami-Tani et al. [20] demonstrates that 1α-D3 supplementation decreases thyroid hormone (fT4, fT3) faster in hyperthyroid phase and increases TSH level faster in achieving euthyroid phase. After euthyroid, there is no difference of fT3 and fT4 levels between the 1α-D3 and placebo groups. In our study, both the mean of fT4 level after supplementation and percentage of fT4 level reduction were not different between both groups. There was an interesting phenomenon on the fT4 changes, i.e., in the placebo group there were two patients who experienced increased fT4 level during the study; while there was no patients in the treatment group who experienced increased fT4 level. It can be a good reason for conducting further studies on vitamin D supplementation in GD.

The response of fT4 level decrement in the first 8 weeks of our study was not as fast as the response found in Kawakami-Tani et al. study. In the Kawakami-Tani et al. study, on the 8th week, the fT4 level reached normal level in both groups and the TSH level began to elevate; while in our study, 8 out of 12 GD patients in the treatment group and 6 out of 13 GD patients in the placebo group still had fT4 level above normal limit and TSH levels had not increased among all patients. The difference in results between our study and Kawakami-Tani et al. study might be influenced by the ATD used; our study used PTU while Kawakami-Tani et al. study used MMI. The transition of hyperthyroid phase to euthyroid phase in our study has not been completed yet; therefore, immunological changes, particularly for DC maturation still cannot be demonstrated.

Study limitation

For a clinical study, the in vivo design of our study has some limitation regarding the number of patients and a relatively short period of supplementation (8 weeks) compared to the previous clinical study (24 weeks) [20]. The small number of patients with heterogeneous patient profiles caused difficulty to observe and to obtain changes in the immune response during the short period observation.
In addition to those factors, the baseline vitamin D level found in the patients also affects the outcomes. The effect of vitamin D supplementation will be more noticeable in patients with low baseline vitamin D level (deficiency and insufficiency). In patients with vitamin D level that close to normal range, as found in our study, we need a longer observation period since the response to vitamin D supplementation tends to occur in sloping trends.

CONCLUSION

The effects of oral 1α-D3 supplementation for 8 weeks on DC maturation of GD patients have not been clearly demonstrated in this study yet.

ACKNOWLEDGMENTS

This study was supported by DIKTI (The Directorate General of Higher Education) Research Grants 2014 and by Division of Endocrinology, Department of Medicine, Faculty of Medicine, Universitas Indonesia. The content is solely the responsibility of authors and does not necessarily represent general view of Universitas Indonesia.

REFERENCES